2018Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes.
Contrasting evidence exists on the comparative efficacy and safety of bivalirudin and unfractionated heparin (UFH) in relation to the planned use of glycoprotein IIb/IIIa inhibitors (GPIs).
- Authors
- Giuseppe Gargiulo, Greta Carrara, Enrico Frigoli, Pascal Vranckx, Sergio Leonardi, Nestor Ciociano, Gianluca Campo, Ferdinando Varbella, Paolo Calabrò, Stefano Garducci, Alessandro Iannone, Carlo Briguori
- Source
- Journal of the American College of Cardiology
- DOI
- 10.1016/j.jacc.2018.01.033
- PubMed
- 29544607
Open original source2019Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome.
The value of prolonged bivalirudin infusion after percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) patients with or without ST-segment elevation remains unclear.
- Authors
- Giuseppe Gargiulo, Greta Carrara, Enrico Frigoli, Sergio Leonardi, Pascal Vranckx, Gianluca Campo, Ferdinando Varbella, Paolo Calabrò, Tiziana Zaro, Davide Bartolini, Carlo Briguori, Giuseppe Andò
- Source
- Journal of the American College of Cardiology
- DOI
- 10.1016/j.jacc.2018.12.023
- PubMed
2003Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
The direct thrombin inhibitor bivalirudin has been associated with better efficacy and less bleeding than heparin during coronary balloon angioplasty but has not been widely tested during contemporary percutaneous coronary intervention (PCI).
- Authors
- A Michael Lincoff, John A Bittl, Robert A Harrington, Frederick Feit, Neal S Kleiman, J Daniel Jackman, Ian J Sarembock, David J Cohen, Douglas Spriggs, Ramin Ebrahimi, Gadi Keren, Jeffrey Carr
- Source
- JAMA
- DOI
- 10.1001/jama.289.7.853
2006Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Bivalirudin for patients with acute coronary syndromes.
Current guidelines for patients with moderate- or high-risk acute coronary syndromes recommend an early invasive approach with concomitant antithrombotic therapy, including aspirin, clopidogrel, unfractionated or low-molecular-weight heparin, and glycoprotein IIb/IIIa inhibitors.
- Authors
- Gregg W Stone, Brent T McLaurin, David A Cox, Michel E Bertrand, A Michael Lincoff, Jeffrey W Moses, Harvey D White, Stuart J Pocock, James H Ware, Frederick Feit, Antonio Colombo, Philip E Aylward
- Source
- The New England journal of medicine
- DOI
- 10.1056/nejmoa062437
- PubMed
2008Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Bivalirudin during primary PCI in acute myocardial infarction.
Treatment with the direct thrombin inhibitor bivalirudin, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, results in similar suppression of ischemia while reducing hemorrhagic complications in patients with stable angina and non-ST-segment elevation acute coronary syndromes who are undergoing percutaneous coronary intervention (PCI).
- Authors
- Gregg W Stone, Bernhard Witzenbichler, Giulio Guagliumi, Jan Z Peruga, Bruce R Brodie, Dariusz Dudek, Ran Kornowski, Franz Hartmann, Bernard J Gersh, Stuart J Pocock, George Dangas, S Chiu Wong
- Source
- The New England journal of medicine
- DOI
- 10.1056/nejmoa0708191
2013Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Bivalirudin started during emergency transport for primary PCI.
Bivalirudin, as compared with heparin and glycoprotein IIb/IIIa inhibitors, has been shown to reduce rates of bleeding and death in patients undergoing primary percutaneous coronary intervention (PCI).
- Authors
- Philippe Gabriel Steg, Arnoud van 't Hof, Christian W Hamm, Peter Clemmensen, Frédéric Lapostolle, Pierre Coste, Jurrien Ten Berg, Pierre Van Grunsven, Gerrit Jan Eggink, Lutz Nibbe, Uwe Zeymer, Marco Campo dell' Orto
- Source
- The New England journal of medicine
- DOI
- 10.1056/nejmoa1311096
- PubMed
- 24171490
2014Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.
Bivalirudin, with selective use of glycoprotein (GP) IIb/IIIa inhibitor agents, is an accepted standard of care in primary percutaneous coronary intervention (PPCI).
- Authors
- Adeel Shahzad, Ian Kemp, Christine Mars, Keith Wilson, Claire Roome, Rob Cooper, Mohammed Andron, Clare Appleby, Mike Fisher, Aleem Khand, Babu Kunadian, Joseph D Mills
- Source
- Lancet (London, England)
- DOI
- 10.1016/s0140-6736(14)60924-7
- PubMed
- 25002178
2015Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes.
Conflicting evidence exists on the efficacy and safety of bivalirudin administered as part of percutaneous coronary intervention (PCI) in patients with an acute coronary syndrome.
- Authors
- Marco Valgimigli, Enrico Frigoli, Sergio Leonardi, Martina Rothenbühler, Andrea Gagnor, Paolo Calabrò, Stefano Garducci, Paolo Rubartelli, Carlo Briguori, Giuseppe Andò, Alessandra Repetto, Ugo Limbruno
- Source
- The New England journal of medicine
- DOI
- 10.1056/nejmoa1507854
- PubMed
- 26324049
Open original source2022Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial.
Previous randomised trials of bivalirudin versus heparin in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) have reported conflicting results, in part because of treatment with different pharmacological regimens.
- Authors
- Yi Li, Zhenyang Liang, Lei Qin, Mian Wang, Xianzhao Wang, Huanyi Zhang, Yin Liu, Yan Li, Zhisheng Jia, Limin Liu, Hongyan Zhang, Jun Luo
- Source
- Lancet (London, England)
- DOI
2025Phase 1–2 human evidence
Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation.
To test feasibility of a randomized controlled trial (RCT) with an endpoint of time at goal anticoagulation in children on extracorporeal membrane oxygenation (ECMO) randomized to receive bivalirudin vs.
- Authors
- Ali McMichael, Jamie Weller, Xilong Li, Laura Hatton, Ayesha Zia, Lakshmi Raman
- Source
- Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
- DOI
- 10.1097/pcc.0000000000003642
- PubMed
- 39585174
Open original source2011Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Pediatric catheterization laboratory anticoagulation with bivalirudin.
Pediatric physicians regularly face the problem of uncertain procedural anticoagulation in children, especially in neonates.
- Authors
- Thomas J Forbes, Ziyad M Hijazi, Guy Young, Jeremy M Ringewald, Paolo M Aquino, Robert N Vincent, Athar M Qureshi, Jonathan J Rome, John F Rhodes, Thomas K Jones, William B Moskowitz, Ralf J Holzer
- Source
- Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
- DOI
- 10.1002/ccd.22817
- PubMed
- 21433272
Open original source1998Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty.
The dosing of anticoagulants during coronary angioplasty is commonly guided by measurements of activated clotting time (ACT), but the usefulness of these measurements remains uncertain.
- Authors
- J A Bittl, W H Ahmed
- Source
- The American journal of cardiology
- DOI
- 10.1016/s0002-9149(98)00760-7
- PubMed
- 9809892
Open original source2023Observational human evidence
Evidence strength B · 72/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Chromogenic and Clot-Based Bivalirudin Assays for Monitoring Anticoagulation.
Direct thrombin inhibitors (DTIs) are usually monitored with the activated partial thromboplastin time (aPTT) or activated clotting time (ACT).
- Authors
- Prashant Raghavendran, Benjamin F Tillman, Allison P Wheeler, David Gailani
- Source
- The journal of applied laboratory medicine
- DOI
- 10.1093/jalm/jfad072
- PubMed
- 37811688
Open original source2023Observational human evidence
Evidence strength A · 88/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials.
The benefit:risk profile of bivalirudin versus heparin anticoagulation in patients with non-ST-segment-elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) is uncertain.
- Authors
- Behnood Bikdeli, David Erlinge, Marco Valgimigli, Adnan Kastrati, Yaling Han, Philippe Gabriel Steg, Rod H Stables, Roxana Mehran, Stefan K James, Enrico Frigoli, Patrick Goldstein, Yi Li
- Source
- Circulation
- DOI
- 10.1161/circulationaha.123.063946
- PubMed
- 37746717
2020Observational human evidence
Evidence strength A · 88/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Meta-analysis of bivalirudin versus heparin in transradial coronary interventions.
We sought to evaluate the efficacy and safety of bivalirudin versus heparin in patients with coronary artery disease undergoing transradial artery coronary intervention (TRI).
- Authors
- Babikir Kheiri, Sunil V Rao, Mohammed Osman, Timothy F Simpson, Mahmoud Barbarawi, Yazan Zayed, Harsukh N Dhillon, Mohamad Alkhouli, Harsh Golwala, Firas Zahr, Deepak L Bhatt, Gregg W Stone
- Source
- Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
- DOI
- 10.1002/ccd.28800
- PubMed
2019Observational human evidence
Evidence strength A · 88/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Bivalirudin with a post-procedure infusion versus heparin monotherapy for the prevention of stent thrombosis.
To evaluate the efficacy of post-primary percutaneous coronary intervention (PCI) bivalirudin infusion (at full PCI dose) to prevent stent thrombosis (ST) compared with heparin monotherapy.
- Authors
- Rahman Shah, Samuel B Latham, Jennifer M Porta, Arshi Naz, Khalid Matin, Sunil V Rao
- Source
- Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
- DOI
- 10.1002/ccd.28065
- PubMed
- 30636368
Open original source2015Observational human evidence
Evidence strength A · 88/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Critical Appraisal of Bivalirudin versus Heparin for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials.
Percutaneous coronary intervention with bivalirudin plus bail-out glycoprotein IIb/IIIa inhibitors has been shown to be as effective as unfractionated heparin plus routine glycoprotein IIb/IIIa inhibitors in preventing cardiac ischemic events, but with a lower bleeding risk.
- Authors
- Anthony A Bavry, Islam Y Elgendy, Ahmed Mahmoud, Manoj P Jadhav, Tianyao Huo
- Source
- PloS one
- DOI
- 10.1371/journal.pone.0127832
- PubMed
- 26010682
Open original source2023Observational human evidence
Evidence strength A · 88/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation.
Bivalirudin has been suggested as an alternative to heparin for anticoagulation in patients receiving extracorporeal membrane oxygenation (ECMO).
- Authors
- Daochao Huang, QiongChan Guan, Jie Qin, Renfei Shan, Jinhong Wu, Chuang Zhang
- Source
- Perfusion
- DOI
- 10.1177/02676591221105605
- PubMed
- 35616224
Open original source2023Observational human evidence
Evidence strength A · 88/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Comparison of Bivalirudin Versus Heparin for Anticoagulation During Extracorporeal Membrane Oxygenation.
The effect and safety of bivalirudin compared with heparin in patients undergoing extracorporeal membrane oxygenation (ECMO) remains unclear.
- Authors
- Daisuke Hasegawa, Ryota Sato, Narut Prasitlumkum, Kazuki Nishida, Brian Keaton, Samuel O Acquah, Young Im Lee
- Source
- ASAIO journal (American Society for Artificial Internal Organs : 1992)
- DOI
- 10.1097/mat.0000000000001814
- PubMed
- 36194483
Open original source2023Observational human evidence
Evidence strength A · 86/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review.
Optimal anticoagulation therapy is essential for the prevention of thrombotic and hemorrhagic complications in pediatric patients supported with extracorporeal membrane oxygenation (ECMO).
- Authors
- Carlos A Valdes, Omar M Sharaf, Mark S Bleiweis, Jeffrey P Jacobs, Mohammed Mumtaz, Ramy M Sharaf, Eric I Jeng, Giles J Peek
- Source
- Frontiers in medicine
- DOI
- 10.3389/fmed.2023.1137134
- PubMed
- 36999064
Open original source2024Observational human evidence
Evidence strength A · 88/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Bivalirudin versus unfractionated heparin in patients with myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis of randomized controlled trials.
Bivalirudin is an alternative accepted therapy to unfractionated heparin for patients with myocardial infarction (MI) undergoing percutaneous coronary intervention (PCI).
- Authors
- Ahmad Al-Abdouh, Mohammed Mhanna, Ahmad Jabri, Luai Madanat, Laith Alhuneafat, Mostafa Reda Mostafa, Amartya Kundu, Vedant Gupta
- Source
- Cardiovascular revascularization medicine : including molecular interventions
- DOI
- 10.1016/j.carrev.2023.10.014
- PubMed
2022Observational human evidence
Evidence strength A · 88/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Is bivalirudin an alternative anticoagulant for extracorporeal membrane oxygenation (ECMO) patients? A systematic review and meta-analysis.
Anticoagulation is important for extracorporeal membrane oxygenation (ECMO).
- Authors
- Di-Huan Li, Ming-Wei Sun, Jian-Cheng Zhang, Chi Zhang, Lei Deng, Hua Jiang
- Source
- Thrombosis research
- DOI
- 10.1016/j.thromres.2021.12.024
- PubMed
- 35007937
Open original source2025Observational human evidence
Evidence strength B · 75/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Evaluation of a Bivalirudin Dosing and Monitoring Protocol in Pediatric Extracorporeal Membrane Oxygenation.
Bivalirudin is a direct thrombin inhibitor used off-label for systemic anticoagulation in extracorporeal membrane oxygenation (ECMO).
- Authors
- Layne M Smith, Francis L Casey Iii, Dhaval Chauhan, Christopher E Mascio, Margaret Mathewson, Jai Udassi
- Source
- The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
- DOI
- 10.5863/1551-6776-30.2.218
- PubMed
- 40717748
Open original source2024Observational human evidence
Evidence strength B · 72/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Effect of bivalirudin on coagulation in neonatal (cord) and adult human blood in vitro.
Bivalirudin is recommended as an alternative to heparin in cardiac surgery with cardiopulmonary bypass.
- Authors
- Sergiy M Nadtochiy, Tatsiana Stefanos, Richard Wissler, Yang Gu, Changyong Feng, Natalie Lebedko, Michael P Eaton
- Source
- Paediatric anaesthesia
- DOI
- 10.1111/pan.14814
- PubMed
- 38055634
Open original source2025Observational human evidence
Evidence strength B · 75/100 · ProvisionalHow this is rated
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
- Directness
- 85/100
- Replication
- 70/100
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Preliminary insights into monitoring bivalirudin anticoagulation: A retrospective cohort study of aPTT versus a chromogenic anti-IIa assay.
Bivalirudin infusions are traditionally monitored with activated partial thromboplastin time (aPTT) despite the poor correlation with bivalirudin dose-response curves.
- Authors
- Sean G Yates, Ravi Sarode, Markus Velten, Jennifer Thibodeau, Abe DeAnda, Ibrahim F Ibrahim, Lisa Skariah
- Source
- Journal of clinical anesthesia
- DOI
- 10.1016/j.jclinane.2025.111836
- PubMed
- 40245747
Open original source